ArticleBritish journal of cancer2010

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

G Mickisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.